Multiple Sclerosis: Immunopathology and Treatment Update

• Published in: Brain sciences Vol. 7; no. 7; p. 78
• Main Authors: Dargahi, Narges, Katsara, Maria, Tselios, Theodore, Androutsou, Maria-Eleni, de Courten, Maximilian, Matsoukas, John, Apostolopoulos, Vasso
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 07-07-2017; MDPI
• Subjects: Copolymer 1; DNA vaccines; drug delivery; Immunosuppressive agents; immunotherapy; Interferon; Mitoxantrone; Monoclonal antibodies; Multiple sclerosis; Nanoparticles; Review; Stem cells; vaccine; vaccine; drug delivery; multiple sclerosis; immunotherapy
• ISSN: 2076-3425; 2076-3425
• DOI: 10.3390/brainsci7070078

The treatment of multiple sclerosis (MS) has changed over the last 20 years. All immunotherapeutic drugs target relapsing remitting MS (RRMS) and it still remains a medical challenge in MS to develop a treatment for progressive forms. The most common injectable disease-modifying therapies in RRMS include β-interferons 1a or 1b and glatiramer acetate. However, one of the major challenges of injectable disease-modifying therapies has been poor treatment adherence with approximately 50% of patients discontinuing the therapy within the first year. Herein, we go back to the basics to understand the immunopathophysiology of MS to gain insights in the development of new improved drug treatments. We present current disease-modifying therapies (interferons, glatiramer acetate, dimethyl fumarate, teriflunomide, fingolimod, mitoxantrone), humanized monoclonal antibodies (natalizumab, ofatumumb, ocrelizumab, alentuzumab, daclizumab) and emerging immune modulating approaches (stem cells, DNA vaccines, nanoparticles, altered peptide ligands) for the treatment of MS.